{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": -1.7391288, "regularMarketPrice": 1.13, "exchange": "NCM", "shortName": "Revelation Biosciences, Inc.", "longName": "Revelation Biosciences, Inc.", "messageBoardId": "finmb_696222591", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 1.541, "fiftyDayAverage": 1.31686, "fiftyDayAverageChange": -0.18685997, "fiftyDayAverageChangePercent": -0.14189813, "twoHundredDayAverage": 7.4457, "twoHundredDayAverageChange": -6.3157, "twoHundredDayAverageChangePercent": -0.84823453, "marketCap": 6638072, "forwardPE": -0.53809524, "priceToBook": 0.7332901, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1668115800, "earningsTimestampStart": 1668115800, "earningsTimestampEnd": 1668115800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -19.77, "epsForward": -2.1, "epsCurrentYear": -20.42, "priceEpsCurrentYear": -0.055337902, "sharesOutstanding": 4511840, "firstTradeDateMilliseconds": 1605623400000, "priceHint": 4, "regularMarketChange": -0.01999998, "regularMarketTime": 1684180805, "regularMarketDayHigh": 1.18, "regularMarketDayRange": "1.11 - 1.18", "regularMarketDayLow": 1.11, "regularMarketVolume": 113946, "regularMarketPreviousClose": 1.15, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 12, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.13, "averageDailyVolume3Month": 760643, "averageDailyVolume10Day": 505680, "fiftyTwoWeekLowChange": 0.17900002, "fiftyTwoWeekLowChangePercent": 0.18822294, "fiftyTwoWeekRange": "0.951 - 67.9", "fiftyTwoWeekHighChange": -66.770004, "fiftyTwoWeekHighChangePercent": -0.9833579, "fiftyTwoWeekLow": 0.951, "fiftyTwoWeekHigh": 67.9, "marketState": "PRE", "symbol": "REVB"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4660 La Jolla Village Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "650 800 3717", "website": "https://www.revbiosciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Rolke", "age": 53, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 400000, "fmt": "400k", "longFmt": "400,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chester Stanley Zygmont III", "age": 42, "title": "CFO & Corp. Sec.", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 320000, "fmt": "320k", "longFmt": "320,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sandra  Vedrick", "title": "VP of HR & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Carol  Odle", "title": "Sr. Director of Clinical Projects", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}